Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases

Asian J Androl. 2020 Jul-Aug;22(4):437-438. doi: 10.4103/aja.aja_66_19.

Authors

Anil Kapoor¹, Nathan C Wong¹, Yuding Wang¹, Som Mukherjee², Sebastien Hotte², Ian Dayes², Himu Lukka²

Affiliations

¹ Division of Urology, Department of Surgery, McMaster University, Hamilton, ON L8N 4A6, USA.
² Department of Oncology, McMaster University, Hamilton, ON L8N 4A6, USA.

No abstract available

Publication types

Letter

MeSH terms

Adenocarcinoma / diagnostic imaging
Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Bone Neoplasms / diagnostic imaging
Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary
Humans
Male
Middle Aged
Progression-Free Survival
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Radioisotopes / therapeutic use
Radionuclide Imaging
Radium / therapeutic use*
Retrospective Studies
Survival Rate

Substances

Antineoplastic Agents
Radioisotopes
radium Ra 223 dichloride
Radium